Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

NCT ID: NCT01553747

Last Updated: 2018-07-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1146 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-29

Study Completion Date

2014-01-09

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Eluxadoline 75 mg

Eluxadoline 75 mg tablets, orally, twice daily for up to 26 weeks period.

Group Type EXPERIMENTAL

Eluxadoline

Intervention Type DRUG

Oral tablets twice daily

Eluxadoline 100 mg

Eluxadoline 100 mg tablets, orally, twice daily for up to 26 weeks period.

Group Type EXPERIMENTAL

Eluxadoline

Intervention Type DRUG

Oral tablets twice daily

Placebo

Eluxadoline placebo matching tablets, orally, twice daily for up to 26 weeks period.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Oral tablets twice daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Eluxadoline

Oral tablets twice daily

Intervention Type DRUG

Placebo

Oral tablets twice daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

JNJ-27018966

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Participant is 18 to 80 years old
2. Participant has a diagnosis of irritable bowel syndrome (IBS) with a subtype of diarrhea defined by the Rome III criteria.

2\. Participant has had a colonoscopy performed:

* Within 10 years prior to Prescreening if participant is at least 50 years of age (sigmoidoscopy, double contrast barium enema, or computed tomography (CT) colonography within the past 5 years is acceptable)
* Since the onset (if applicable) of any of the following alarm features for participants of any age

* Participant has documented weight loss within the past 6 months
* Participant has nocturnal symptoms
* Participant has a familial history of first-degree relatives with colon cancer
* Participant has blood mixed with their stool (excluding blood from hemorrhoids).

3\. Female participants must be:
* Postmenopausal, defined as 52 years or older and amenorrheic for at least 2 years at Prescreening,
* Surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),
* Abstinent, or
* If sexually active, be practicing an effective method of birth control.

Exclusion Criteria

1. Participant has a diagnosis of IBS with a subtype of constipation, mixed IBS, or unsubtyped IBS by the Rome III criteria.
2. Participant has a history of inflammatory or immune-mediated gastrointestinal (GI) disorders including inflammatory bowel disease (ie, Crohn's disease, ulcerative colitis) and celiac disease.
3. Participant has a history of diverticulitis within 3 months prior to Prescreening.
4. Participant has a history of intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic colitis, or impaired intestinal circulation (eg, aortoiliac disease).
5. Participant has any of the following surgical history:

* Cholecystectomy with any history of post cholecystectomy biliary tract pain
* Any abdominal surgery within the 3 months prior to Prescreening
* Participant has a history of major gastric, hepatic, pancreatic, or intestinal surgery (appendectomy, hemorrhoidectomy, or polypectomy greater than 3 months post surgery are allowed)

Other protocol-specific eligibility criteria may apply.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Furiex Pharmaceuticals, Inc

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Furiex Research Site

Birmingham, Alabama, United States

Site Status

Furiex Research Site

Birmingham, Alabama, United States

Site Status

Furiex Research Site

Decatur, Alabama, United States

Site Status

Furiex Research Site

Huntsville, Alabama, United States

Site Status

Furiex Research Site

Mobile, Alabama, United States

Site Status

Furiex Research Site

Montgomery, Alabama, United States

Site Status

Furiex Research Site

Sheffield, Alabama, United States

Site Status

Furiex Research Site

Tuscaloosa, Alabama, United States

Site Status

Furiex Research Site

Glendale, Arizona, United States

Site Status

Furiex Research Site

Glendale, Arizona, United States

Site Status

Furiex Research Site

Mesa, Arizona, United States

Site Status

Furiex Research Site

Phoenix, Arizona, United States

Site Status

Furiex Research Site

Phoenix, Arizona, United States

Site Status

Furiex Research Site

Tucson, Arizona, United States

Site Status

Furiex Research Site

Tucson, Arizona, United States

Site Status

Furiex Research Site

Jonesboro, Arkansas, United States

Site Status

Furiex Research Site

Little Rock, Arkansas, United States

Site Status

Furiex Research Site

Sherwood, Arkansas, United States

Site Status

Furiex Research Site

Anaheim, California, United States

Site Status

Furiex Research Site

Chula Vista, California, United States

Site Status

Furiex Research Site

Encinitas, California, United States

Site Status

Furiex Research Site

Garden Grove, California, United States

Site Status

Furiex Research Site

Huntington Beach, California, United States

Site Status

Furiex Research Site

Irvine, California, United States

Site Status

Furiex Research Site

La Mesa, California, United States

Site Status

Furiex Research Site

La Mirada, California, United States

Site Status

Furiex Research Site

Laguna Hills, California, United States

Site Status

Furiex Research Site

Lakewood, California, United States

Site Status

Furiex Research Site

Lincoln, California, United States

Site Status

Furiex Research Site

Loma Linda, California, United States

Site Status

Furiex Research Site

Lomita, California, United States

Site Status

Furiex Research Site

Long Beach, California, United States

Site Status

Furiex Research Site

Los Angeles, California, United States

Site Status

Furiex Research Site

Newport Beach, California, United States

Site Status

Furiex Research Site

North Hollywood, California, United States

Site Status

Furiex Research Site

Northridge, California, United States

Site Status

Furiex Research Site

Pasadena, California, United States

Site Status

Furiex Research Site

Sacramento, California, United States

Site Status

Furiex Research Site

San Diego, California, United States

Site Status

Furiex Research Site

San Diego, California, United States

Site Status

Furiex Research Site

Santa Ana, California, United States

Site Status

Furiex Research Site

Ventura, California, United States

Site Status

Furiex Research Site

Walnut Creek, California, United States

Site Status

Furiex Research Site

Denver, Colorado, United States

Site Status

Furiex Research Site

Denver, Colorado, United States

Site Status

Furiex Research Site

Boca Raton, Florida, United States

Site Status

Furiex Research Site

Boynton Beach, Florida, United States

Site Status

Furiex Research Site

Bradenton, Florida, United States

Site Status

Furiex Research Site

Brooksville, Florida, United States

Site Status

Furiex Research Site

Clearwater, Florida, United States

Site Status

Furiex Research Site

Cooper City, Florida, United States

Site Status

Furiex Research Site

Coral Springs, Florida, United States

Site Status

Furiex Research Site

Eustis, Florida, United States

Site Status

Furiex Research Site

Fort Lauderdale, Florida, United States

Site Status

Furiex Research Site

Hallandale, Florida, United States

Site Status

Furiex Research Site

Hialeah, Florida, United States

Site Status

Furiex Research Site

Jacksonville, Florida, United States

Site Status

Furiex Research Site

Jupiter, Florida, United States

Site Status

Furiex Research Site

Lauderdale Lakes, Florida, United States

Site Status

Furiex Research Site

Melbourne, Florida, United States

Site Status

Furiex Research Site

Miami, Florida, United States

Site Status

Furiex Research Site

Miami, Florida, United States

Site Status

Furiex Research Site

Miami, Florida, United States

Site Status

Furiex Research Site

Miami, Florida, United States

Site Status

Furiex Research Site

Miami, Florida, United States

Site Status

Furiex Research Site

Miami, Florida, United States

Site Status

Furiex Research Site

Miami, Florida, United States

Site Status

Furiex Research Site

Miami, Florida, United States

Site Status

Furiex Research Site

Miramar, Florida, United States

Site Status

Furiex Research Site

New Port Richey, Florida, United States

Site Status

Furiex Research Site

Orlando, Florida, United States

Site Status

Furiex Research Site

Plant City, Florida, United States

Site Status

Furiex Research Site

Port Orange, Florida, United States

Site Status

Furiex Research Site

South Miami, Florida, United States

Site Status

Furiex Research Site

St. Petersburg, Florida, United States

Site Status

Furiex Research Site

St. Petersburg, Florida, United States

Site Status

Furiex Research Site

Tampa, Florida, United States

Site Status

Furiex Research Site

Wellington, Florida, United States

Site Status

Furiex Research Site

Winter Haven, Florida, United States

Site Status

Furiex Research Site

Winter Park, Florida, United States

Site Status

Furiex Research Site

Alpharetta, Georgia, United States

Site Status

Furiex Research Site

Athens, Georgia, United States

Site Status

Furiex Research Site

Atlanta, Georgia, United States

Site Status

Furiex Research Site

Atlanta, Georgia, United States

Site Status

Furiex Research Site

Dunwoody, Georgia, United States

Site Status

Furiex Research Site

Lawrenceville, Georgia, United States

Site Status

Furiex Research Site

Macon, Georgia, United States

Site Status

Furiex Research Site

Marietta, Georgia, United States

Site Status

Furiex Research Site

Norcross, Georgia, United States

Site Status

Furiex Research Site

Savannah, Georgia, United States

Site Status

Furiex Research Site

Stockbridge, Georgia, United States

Site Status

Furiex Research Site

Boise, Idaho, United States

Site Status

Furiex Research Site

Eagle, Idaho, United States

Site Status

Furiex Research Site

Idaho Falls, Idaho, United States

Site Status

Furiex Research Site

Addison, Illinois, United States

Site Status

Furiex Research Site

Chicago, Illinois, United States

Site Status

Furiex Research Site

Chicago, Illinois, United States

Site Status

Furiex Research Site

Evergreen Park, Illinois, United States

Site Status

Furiex Research Site

Hammond, Illinois, United States

Site Status

Furiex Research Site

Springfield, Illinois, United States

Site Status

Furiex Research Site

Brownsburg, Indiana, United States

Site Status

Furiex Research Site

Evansville, Indiana, United States

Site Status

Furiex Research Site

Granger, Indiana, United States

Site Status

Furiex Research Site

Clive, Iowa, United States

Site Status

Furiex Research Site

Pratt, Kansas, United States

Site Status

Furiex Research Site

Shawnee Mission, Kansas, United States

Site Status

Furiex Research Site

Topeka, Kansas, United States

Site Status

Furiex Research Site

Lexington, Kentucky, United States

Site Status

Furiex Research Site

Lexington, Kentucky, United States

Site Status

Furiex Research Site

Owensboro, Kentucky, United States

Site Status

Furiex Research Site

Paducah, Kentucky, United States

Site Status

Furiex Research Site

Lake Charles, Louisiana, United States

Site Status

Furiex Research Site

Monroe, Louisiana, United States

Site Status

Furiex Research Site

Hagerstown, Maryland, United States

Site Status

Furiex Research Site

Hollywood, Maryland, United States

Site Status

Furiex Research Site

Boston, Massachusetts, United States

Site Status

Furiex Research Site

Boston, Massachusetts, United States

Site Status

Furiex Research Site

Brockton, Massachusetts, United States

Site Status

Furiex Research Site

Watertown, Massachusetts, United States

Site Status

Furiex Research Site

Ann Arbor, Michigan, United States

Site Status

Furiex Research Site

Bay City, Michigan, United States

Site Status

Furiex Research Site

Cadillac, Michigan, United States

Site Status

Furiex Research Site

Grand Rapids, Michigan, United States

Site Status

Furiex Research Site

Kalamazoo, Michigan, United States

Site Status

Furiex Research Site

Troy, Michigan, United States

Site Status

Furiex Research Site

Ypsilanti, Michigan, United States

Site Status

Furiex Research Site

Plymouth, Minnesota, United States

Site Status

Furiex Research Site

Biloxi, Mississippi, United States

Site Status

Furiex Research Site

City of Saint Peters, Missouri, United States

Site Status

Furiex Research Site

Hazelwood, Missouri, United States

Site Status

Furiex Research Site

St Louis, Missouri, United States

Site Status

Furiex Research Site

St Louis, Missouri, United States

Site Status

Furiex Research Site

St Louis, Missouri, United States

Site Status

Furiex Research Site

Billings, Montana, United States

Site Status

Furiex Research Site

Bellevue, Nebraska, United States

Site Status

Furiex Research Site

Elkhorn, Nebraska, United States

Site Status

Furiex Research Site

Lincoln, Nebraska, United States

Site Status

Furiex Research Site

Omaha, Nebraska, United States

Site Status

Furiex Research Site

Omaha, Nebraska, United States

Site Status

Furiex Research Site

Las Vegas, Nevada, United States

Site Status

Furiex Research Site

Reno, Nevada, United States

Site Status

Furiex Research Site

Lebanon, New Hampshire, United States

Site Status

Furiex Research Site

Blackwood, New Jersey, United States

Site Status

Furiex Research Site

Edison, New Jersey, United States

Site Status

Furiex Research Site

Elizabeth, New Jersey, United States

Site Status

Furiex Research Site

Marlton, New Jersey, United States

Site Status

Furiex Research Site

Albuquerque, New Mexico, United States

Site Status

Furiex Research Site

Albuquerque, New Mexico, United States

Site Status

Furiex Research Site

Albuquerque, New Mexico, United States

Site Status

Furiex Research Site

Flushing, New York, United States

Site Status

Furiex Research Site

Hollis, New York, United States

Site Status

Furiex Research Site

Mineola, New York, United States

Site Status

Furiex Research Site

New York, New York, United States

Site Status

Furiex Research Site

Chapel Hill, North Carolina, United States

Site Status

Furiex Research Site

Dunn, North Carolina, United States

Site Status

Furiex Research Site

Greensboro, North Carolina, United States

Site Status

Furiex Research Site

Huntersville, North Carolina, United States

Site Status

Furiex Research Site

Kinston, North Carolina, United States

Site Status

Furiex Research Site

Wilmington, North Carolina, United States

Site Status

Furiex Research Site

Winston-Salem, North Carolina, United States

Site Status

Furiex Research Site

Winston-Salem, North Carolina, United States

Site Status

Furiex Research Site

Akron, Ohio, United States

Site Status

Furiex Research Site

Beavercreek, Ohio, United States

Site Status

Furiex Research Site

Cincinnati, Ohio, United States

Site Status

Furiex Research Site

Cincinnati, Ohio, United States

Site Status

Furiex Research Site

Cincinnati, Ohio, United States

Site Status

Furiex Research Site

Cincinnati, Ohio, United States

Site Status

Furiex Research Site

Cleveland, Ohio, United States

Site Status

Furiex Research Site

Columbus, Ohio, United States

Site Status

Furiex Research Site

Columbus, Ohio, United States

Site Status

Furiex Research Site

Columbus, Ohio, United States

Site Status

Furiex Research Site

Dayton, Ohio, United States

Site Status

Furiex Research Site

Dayton, Ohio, United States

Site Status

Furiex Research Site

Groveport, Ohio, United States

Site Status

Furiex Research Site

Kettering, Ohio, United States

Site Status

Furiex Research Site

Lima, Ohio, United States

Site Status

Furiex Research Site

Tiffin, Ohio, United States

Site Status

Furiex Research Site

Toledo, Ohio, United States

Site Status

Furiex Research Site

Norman, Oklahoma, United States

Site Status

Furiex Research Site

Oklahoma City, Oklahoma, United States

Site Status

Furiex Research Site

Oklahoma City, Oklahoma, United States

Site Status

Furiex Research Site

Portland, Oregon, United States

Site Status

Furiex Research Site

Salem, Oregon, United States

Site Status

Furiex Research Site

Carnegie, Pennsylvania, United States

Site Status

Furiex Research Site

Philadelphia, Pennsylvania, United States

Site Status

Furiex Research Site

Pittsburgh, Pennsylvania, United States

Site Status

Furiex Research Site

Pittsburgh, Pennsylvania, United States

Site Status

Furiex Research Site

Scottdale, Pennsylvania, United States

Site Status

Furiex Research Site

Uniontown, Pennsylvania, United States

Site Status

Furiex Research Site

Warwick, Rhode Island, United States

Site Status

Furiex Research Site

Anderson, South Carolina, United States

Site Status

Furiex Research Site

Columbia, South Carolina, United States

Site Status

Furiex Research Site

Columbia, South Carolina, United States

Site Status

Furiex Research Site

Columbia, South Carolina, United States

Site Status

Furiex Research Site

Easley, South Carolina, United States

Site Status

Furiex Research Site

Mt. Pleasant, South Carolina, United States

Site Status

Furiex Research Site

North Myrtle Beach, South Carolina, United States

Site Status

Furiex Research Site

Rapid City, South Dakota, United States

Site Status

Furiex Research Site

Athens, Tennessee, United States

Site Status

Furiex Research Site

Chattanooga, Tennessee, United States

Site Status

Furiex Research Site

Columbia, Tennessee, United States

Site Status

Furiex Research Site

Jackson, Tennessee, United States

Site Status

Furiex Research Site

Knoxville, Tennessee, United States

Site Status

Furiex Research Site

Smyrna, Tennessee, United States

Site Status

Furiex Research Site

Austin, Texas, United States

Site Status

Furiex Research Site

Beaumont, Texas, United States

Site Status

Furiex Research Site

Bedford, Texas, United States

Site Status

Furiex Research Site

Corsicana, Texas, United States

Site Status

Furiex Research Site

Dallas, Texas, United States

Site Status

Furiex Research Site

Dallas, Texas, United States

Site Status

Furiex Research Site

Fort Worth, Texas, United States

Site Status

Furiex Research Site

Frisco, Texas, United States

Site Status

Furiex Research Site

Houston, Texas, United States

Site Status

Furiex Research Site

Houston, Texas, United States

Site Status

Furiex Research Site

Houston, Texas, United States

Site Status

Furiex Research Site

Humble, Texas, United States

Site Status

Furiex Research Site

Hurst, Texas, United States

Site Status

Furiex Research Site

San Antonio, Texas, United States

Site Status

Furiex Research Site

San Antonio, Texas, United States

Site Status

Furiex Research Site

San Antonio, Texas, United States

Site Status

Furiex Research Site

Bountiful, Utah, United States

Site Status

Furiex Research Site

Salt Lake City, Utah, United States

Site Status

Furiex Research Site

West Valley City, Utah, United States

Site Status

Furiex Research Site

Burlington, Vermont, United States

Site Status

Furiex Research Site

Alexandria, Virginia, United States

Site Status

Furiex Research Site

Christiansburg, Virginia, United States

Site Status

Furiex Research Site

Midlothian, Virginia, United States

Site Status

Furiex Research Site

Norfolk, Virginia, United States

Site Status

Furiex Research Site

Richmond, Virginia, United States

Site Status

Furiex Research Site

Richmond, Virginia, United States

Site Status

Furiex Research Site

Charleston, West Virginia, United States

Site Status

Furiex Research Site

Monroe, Wisconsin, United States

Site Status

Furiex Research Site

Kelowna, British Columbia, Canada

Site Status

Furiex Research Site

St. John's, Newfoundland and Labrador, Canada

Site Status

Furiex Research Site

Burlington, Ontario, Canada

Site Status

Furiex Research Site

Greater Sudbury, Ontario, Canada

Site Status

Furiex Research Site

Hawkesbury, Ontario, Canada

Site Status

Furiex Research Site

London, Ontario, Canada

Site Status

Furiex Research Site

Newmarket, Ontario, Canada

Site Status

Furiex Research Site

Sarnia, Ontario, Canada

Site Status

Furiex Research Site

Toronto, Ontario, Canada

Site Status

Furiex Research Site

Vaughan, Ontario, Canada

Site Status

Furiex Research Site

San Juan, , Puerto Rico

Site Status

Furiex Research Site

Chestfield, Kent, United Kingdom

Site Status

Furiex Research Site

Blackpool, Lancashire, United Kingdom

Site Status

Furiex Research Site

Birmingham, , United Kingdom

Site Status

Furiex Research Site

County Durham, , United Kingdom

Site Status

Furiex Research Site

Coventry, , United Kingdom

Site Status

Furiex Research Site

Durham, , United Kingdom

Site Status

Furiex Research Site

Edinburgh, , United Kingdom

Site Status

Furiex Research Site

Manchester, , United Kingdom

Site Status

Furiex Research Site

Sheffield, , United Kingdom

Site Status

Furiex Research Site

Wigan, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Puerto Rico United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Fant RV, Henningfield JE, Cash BD, Dove LS, Covington PS. Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea. Clin Gastroenterol Hepatol. 2017 Jul;15(7):1021-1029.e6. doi: 10.1016/j.cgh.2017.01.026. Epub 2017 Feb 3.

Reference Type DERIVED
PMID: 28167156 (View on PubMed)

Lembo AJ, Lacy BE, Zuckerman MJ, Schey R, Dove LS, Andrae DA, Davenport JM, McIntyre G, Lopez R, Turner L, Covington PS. Eluxadoline for Irritable Bowel Syndrome with Diarrhea. N Engl J Med. 2016 Jan 21;374(3):242-53. doi: 10.1056/NEJMoa1505180.

Reference Type DERIVED
PMID: 26789872 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2012-001601-24

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

27018966IBS3002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.